AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

Tesla stock extends gains after the electric-vehicle maker’s market cap closes above $1 trillion for the first time since ...

Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...

Stocks rose to new record highs again Monday, while bitcoin hit all-time highs of its own above $84,000, as the election-fueled rally continues.

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.

However, this does not break the investment thesis on AbbVie as the company is diversified enough to carry on and continue to ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...

AbbVie said a recently acquired drug candidate for schizophrenia ... a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said Monday. The North Chicago, ...